Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BoBin Biology is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the field of targeted protein degradation (TPD). The company leverages its proprietary platform to develop next-generation Proteolysis-Targeting Chimeras (PROTACs) and molecular glues designed to address "undruggable" targets in oncology and immunology. Its lead candidate, BB-101, is an orally bioavailable androgen receptor degrader currently in Phase 1 clinical trials for metastatic castration-resistant prostate cancer. BoBin Biology's pipeline also includes degraders for the estrogen receptor and STAT3, aiming to overcome resistance to existing therapies. The company was founded by industry veterans with significant experience in TPD and is backed by leading venture capital firms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bobin Biology.